Ragon Institute

Program for Immune Engineering

Leveraging discoveries to develop cutting-edge diagnostics and treatments

Our Focus

The Program for Immune Engineering is dedicated to leveraging the immune system’s intricacies to drive practical solutions that improve human health. While it builds on fundamental insights into how immunity is maintained and how it falters, its primary focus is on applying these discoveries to engineer innovative strategies for disease prevention, detection, and treatment.

Building on these foundational principles, the program embraces a range of interconnected efforts that collectively strengthen our ability to harness immunity. Some undertakings focus on proactively preventing disease before it takes hold, preparing the body to ward off future challenges. Others center on refining the methods we use to identify health threats early, ensuring prompt and effective intervention. Additionally, these initiatives aim to fine-tune the immune response itself, providing strategies that either bolster the body’s defenses or temper overactive responses.

By weaving together prevention, detection, and the careful modulation of immune activity, the Program for Immune Engineering identifies cutting-edge solutions to enhance immune responses and protect against emerging global health threats, as well as detecting and developing different assays to assist with and advance research processes. This program is pivotal in advancing the understanding of immune mechanisms and applying these findings to create therapies that can address a wide range of diseases, ensuring that the immune system can adapt and respond effectively to the evolving landscape of human health.

Our Initiatives

Vaccine Development

The Vaccine Development initiative focuses on creating agents that provide active acquired immunity against infectious diseases and cancers. By developing vaccines that target specific pathogens or malignant cells, this research aims to prevent disease and stimulate the immune system to recognize and fight harmful agents before they cause illness. Additionally, it can develop means to optimize vaccine efficacy as well as identify potential paths towards vaccines. The initiative is critical for preparing against both current and future health threats, with the goal of producing safe, effective vaccines that offer long-term protection.

Diagnostics & Devices

The Diagnostics & Devices initiative is dedicated to the creation of tools and assays. These devices range from tools for early diagnosis, to means for experimental optimization, to advanced research instruments that assist in studying disease progression. By developing innovative diagnostic devices, this initiative enhances the ability to further advance science and speed up research, ultimately enabling faster and more accurate healthcare interventions.

Immune Therapies

The Immune Therapies initiative focuses on developing treatments that either activate or suppress the immune system to treat disease. By manipulating the immune system’s response, these therapies can help fight infections, cancers, and autoimmune diseases amongst other. This research aims to design therapies that restore proper immune function or enhance the body’s natural defense mechanisms, providing targeted treatment for various conditions.

Research Highlights

New HIV Vaccine Design Shows Promise in Creating Protective Antibodies

Sep 3, 2024 Features

Researchers at the University of Amsterdam, in collaboration with the Batista Lab at the Ragon Institute, have developed a potential new approach for an HIV vaccine. The study, published in Science Immunology, focuses on creating a vaccine component that can stimulate the immune system to produce powerful antibodies against HIV. Titled “Germline-targeting HIV vaccination induces neutralizing antibodies to the CD4 […]

Alex Shalek Appointed Director of IMES at MIT

Jul 30, 2024 Features

We are thrilled to announce that Ragon faculty member Alex Shalek, PhD, has been appointed as the new Director of the Institute for Medical Engineering and Science (IMES) at MIT, effective August 1, 2024. Shalek joined the Ragon Institute a decade ago, playing a pivotal role in advancing our mission. His innovative work spans genomics, […]

Evavold Presents at RCCHU Seminar

Jul 16, 2024 Features

On July 9, Ragon faculty member and Early Independence Fellow Charles Evavold, PhD, participated in a special seminar as part of the Science Seminar Series @RCCHU titled “Synthetic Biology Strategies for Human Health: From Yeasts to Immune Cells.” Hosted by the Real Colegio Complutense at Harvard (RCCHU) and Harvard Medical School, this seminar explored innovative […]

New target in sight for HIV vaccine development

May 30, 2024 Features

Batista Lab postdoctoral fellow Rashmi Ray, PhD, was the first author of the paper published in Nature. Decades into the HIV epidemic, there is as yet no effective vaccine to prevent new cases. In a recent Nature Immunology article (Ray et al.), the Batista lab of the Ragon Institute has preclinically validated a new HIV […]

Related Labs

Allen Lab

Principal Investigator

Todd Allen, PhD

  • T Cell Immunotherapy
  • HIV Evolution and Transmission

Balazs Lab

Principal Investigator

Alejandro B. Balazs, PhD

  • Engineering Immunity Against Infectious Disease

Barczak Lab

Principal Investigator

Amy Barczak, MD

  • Host-pathogen interactions in mycobacterial infection

Batista Lab

Principal Investigator

Facundo Batista, PhD

  • B cells
  • Antibodies
  • Preclinical vaccinology

Bryson Lab

Principal Investigator

Bryan Bryson, PhD

  • Immune control of mycobacteria

Dekosky Lab

Principal Investigator

Brandon J. DeKosky, PhD

  • Efficient Engineering and Discovery of Adaptive Immune Receptors

Evavold Lab

Principal Investigator

Charles Evavold, PhD

  • Synthetic immunity and cell death regulation

Gaiha Lab

Principal Investigator

Gaurav D. Gaiha, MD, DPhil

  • T cells
  • Vaccines
  • Immune Control

Garcia-Beltran Lab

Principal Investigator

Wilfredo Garcia-Beltran, MD, PhD

  • NK cell biology
  • Immune/cellular therapy

Ghebremichael Lab

Principal Investigator

Musie Ghebremichael, PhD

  • Application and development of statistical methods

Juelg Lab

Principal Investigator

Boris D. Juelg, MD, PhD

  • Natural infections informing immunotherapies

Kwon Lab

Principal Investigator

Douglas S. Kwon, MD, PhD

  • Mucosal Immunology
  • Microbiome
  • HIV
  • Clinical Research
  • Emerging Infectious Diseases

Lichterfeld Lab

Principal Investigator

Mathias D. Lichterfeld, MD, PhD

  • Clinical Trials
  • Single Cell assays
  • HIV Cure

Lingwood Lab

Principal Investigator

Daniel Lingwood, PhD

  • Programing vaccine antibody responses

Liu Lab

Principal Investigator

Sophia Liu, PhD

  • Building tools to characterize spatial and temporal immune cell interactions

Pillai Lab

Principal Investigator

Shiv Pillai, MD, PhD

  • B-cell biology and T-B collaboration

Ringel Lab

Principal Investigator

Alison Ringel, PhD

  • Molecular adaptations in immune cells enabling function under stress

Schmidt Lab

Principal Investigator

Aaron Schmidt, PhD

  • Protein Engineering
  • Therapeutic Development
  • Viral Evolution

Shalek Lab

Principal Investigator

Alex K. Shalek, PhD

  • Single-Cell Genomics
  • Systems Immunology

Walker Lab

Principal Investigator

Bruce D. Walker, MD

  • HIV
  • Virus-specific T cells
  • Elite controllers

Wong Lab

Principal Investigator

Harikesh Wong, PhD

  • Intercellular Communication
  • Tissue Microenvironment
  • Quantitative & Systems Immunology

Program for Immunophysiology and Disease

Revealing mechanisms of immune control and disease pathogenesis to prepare for and protect against future global health threats.

Program for Patient Focused Immunology

Bringing observations from the bedside to the bench and back, worldwide.